Results 121 to 130 of about 22,239 (295)

Exploring the clinical utility of DPP-IV and SGLT2 inhibitors in papillary thyroid cancer: a literature review

Frontiers in Pharmacology
In the realm of clinical management, Papillary Thyroid Cancer (PTC) stands out as a prevalent thyroid malignancy, characterized by significant metabolic challenges, particularly in the context of carbohydrate metabolism.
Angelika Buczyńska, Maria Kościuszko, Adam Jacek Krętowski, Adam Jacek Krętowski, Anna Popławska-Kita   +4 more
doaj   +1 more source

Sitagliptin, Metformin and Glimepiride Fixed‐Dose Combination Compared to Co‐Administration of Metformin and High‐Dose Glimepiride in Indian Patients With Type 2 Diabetes: A Randomised, Double‐Blind, Double‐Dummy, Phase 3 Clinical Study

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims This study assessed the efficacy and safety of a triple fixed‐dose combination (FDC) of sitagliptin, metformin, and glimepiride versus co‐administered metformin and glimepiride in Indian patients with uncontrolled Type 2 diabetes (T2D).
Rakesh Sahay, Ambanna Gowda, Manish Kumar Singh, A. Gopal Rao, Ramesh Duraisamy, Dinesh Gangwani, Jitendra Shukla, Vikas Agarwal, Sandesh Sahebarao Patil, Ambrish C., Satish Babu K. N., Arvind Palawat, Sandip Krishnrao Gofne, Abhay Kumar Sahoo, Pradeep Kumar Rai, Raisa Shaikh, Shruti Saha, Dipak Patil, Pravin Ghadge, Piyush Patel, Lalit Lakhwani, Suyog Mehta, Sadhna Joglekar   +22 more
wiley   +1 more source

Bifidobacterium bifidum G9‐1 Intake Improves Gastrointestinal Symptoms in Type 2 Diabetes Mellitus: An Open‐Label, Randomized Controlled Trial (Binary STAR Study)

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To evaluate the effects of probiotics Bifidobacterium bifidum G9‐1 (BBG9‐1) on gastrointestinal symptoms in patients with Type 2 diabetes mellitus (T2DM) with diarrhoea or constipation. Materials and Methods In a 12‐week open‐label randomised controlled trial, 100 participants were randomized 1:1 to a control or BBG9‐1 group, with 12 mg ...
Genki Kobayashi, Yoshitaka Hashimoto, Tomoyuki Matsuyama, Noriyuki Kitagawa, Saori Majima, Takafumi Senmaru, Emi Ushigome, Hiroshi Okada, Naoko Nakanishi, Masahide Hamaguchi, Michiaki Fukui   +10 more
wiley   +1 more source

Glycaemic Control According to the Final Insulin Dose Using an Innovative Fixed‐Dose Titration of Weekly Insulin Efsitora in Insulin‐Naïve Type 2 Diabetes

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims In the QWINT‐1 phase 3 Trial, once‐weekly insulin efsitora alfa (efsitora) administered using an innovative fixed‐dose regimen demonstrated noninferior HbA1c reduction versus once‐daily insulin glargine U100 (glargine) over 52 weeks in insulin‐naïve adults with type 2 diabetes.
Lisa Connery, Julio Rosenstock, Neda Rasouli, Alice Y. Y. Cheng, Andreas Liebl, Qianqian Wang, Vitoria Pires, Alastair Knights, Michael B. Davidson, Christopher J. Child   +9 more
wiley   +1 more source

The perceptions of natural compounds against dipeptidyl peptidase 4 in diabetes: from to

Therapeutic Advances in Chronic Disease, 2019
Dipeptidyl peptidase IV (DPP-4), an incretin glucagon-like peptide-1 (GLP-1) degrading enzyme, contains two forms and it can exert various physiological functions particular in controlling blood glucose through the action of GLP-1.
Shian-Ren Lin, Chia-Hsiang Chang, May-Jwan Tsai, Henrich Cheng, Jian-Chyi Chen, Max K. Leong, Ching-Feng Weng   +6 more
doaj   +1 more source

Az entero-inzularis tengely (dipeptidyl peptidase-4-incretin rendszer) jelentősége diabetesben és különböző kóros glükóztoleranciával járó állapotokban = Significance of the entero-insular axis (dipeptidyl peptidase-4–incretin system) in diabetes and in various conditions with impaired glucose tolerance [PDF]

, 2011
• Az éhomi szérum DPP-4 aktivitás nem magasabb 2-es típusú cukorbetegekben (T2DM), ha –klinikailag a nem alkoholos zsírmájbetegséget (NAFLD) a csoportból kizárjuk.
Firneisz, Gábor
core  

Association Between SGLT2 Inhibitors and DPP‐4 Inhibitors Use and Risk of Acute Pancreatitis: Findings From Nationwide Case‐Based Analyses

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims The Korean national health insurance claims database was utilised to investigate the association between sodium–glucose cotransporter 2 inhibitors (SGLT2i) or dipeptidyl peptidase‐4 inhibitors (DPP‐4i) and the risk of acute pancreatitis (AP). Materials and Methods Patients with type 2 diabetes mellitus prescribed DPP‐4i or SGLT2i at least
Ye‐Jee Kim, Yun Kyung Cho, Mi‐Sook Kim, Joongyub Lee, Seonghae Kim, Bo Ram Yang   +5 more
wiley   +1 more source

Use of Dipeptidyl-Peptidase IV Inhibitors and Bullous Pemphigoid [PDF]

Dermatology, 2017
Schaffer, Clara, Buclin, Thierry, Jornayvaz, François, Cazzaniga, Simone, Borradori, Luca, Gilliet, Michel, Feldmeyer, Laurence   +6 more
openaire   +5 more sources

Association Between Glucagon‐Like Peptide‐1 Receptor Agonists and Suicidality: A Systematic Review

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims We aimed to examine the association between GLP‐1 RA use and suicidal ideation or behaviours through a systematic review of observational studies. Materials and Methods A comprehensive search of MEDLINE, PubMed, EMBASE, CINAHL and PsycINFO was conducted from database inception through December 11, 2025. Observational studies investigating
Timothy H. Chan, Leon E. Cosler, Michael R. Gionfriddo, Emily E. Leppien, Eleanor J. Sommers, Mia E. Lussier   +5 more
wiley   +1 more source

CD26/DPPIV and response to hepatitis B vaccination [PDF]

, 2004
The prevention of hepatitis B is important, since it is responsible for significant morbidity and mortality around the world. Unfortunately, hepatitis B vaccine does not always induce protective immunity.
Alves, V, Dourado, M, Mesquita, L, Pinto, AM, Ramos, I, Rosa, MS   +5 more
core